Mylan Institutional Drug Patent Portfolio
Mylan Institutional owns 1 orange book drug protected by 2 US patents Given below is the list of Mylan Institutional's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5866591 | Stable formulations of remifentanil | 10 Mar, 2018 | Expired |
| US5866591 | Stable formulations of remifentanil | 10 Sep, 2017 | Expired |
Mylan Institutional's Family Patents
Recent FDA approvals and tentative approvals for Mylan Institutional
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Innovator drugs
Includes innovator drug submissions that appear in FDA approval and tentative approval disclosures.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Efavirenz, Emtricitabine And Tenofovir Alafenamide |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Type 4 - New Combination | 22 Mar, 2024 |
| Darunavir And Ritonavir |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Type 4 - New Combination | 22 Dec, 2023 |
| Dolutegravir, Lamivudine, And Tenofovir Disoproxil Fumarate |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Type 4 - New Combination | 02 Aug, 2017 |
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Aprepitant |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 17 Nov, 2025 |
| Paliperidone Palmitate |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 03 Dec, 2024 |
| Sugammadex |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 20 Nov, 2024 |
Mylan Institutional Drug List
Given below is the complete list of Mylan Institutional's drugs and the patents protecting them.
1. Ultiva
Ultiva is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5866591
(Pediatric)
| Stable formulations of remifentanil |
10 Mar, 2018
(7 years ago)
| Expired |
| US5866591 | Stable formulations of remifentanil |
10 Sep, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ultiva's drug page